作者
Jedd D. Wolchok,Vanna Chiarion‐Sileni,Piotr Rutkowski,C. Lance Cowey,Dirk Schadendorf,John Wagstaff,Paola Queirolo,Reinhard Dummer,Marcus O. Butler,Andrew G. Hill,Michael A. Postow,C. Gaudy‐Marqueste,Theresa Medina,Christopher D. Lao,John R. Walker,Iván Márquez‐Rodas,John B.A.G. Haanen,Massimo Guidoboni,Michele Maio,Patrick Schöffski,Matteo S. Carlino,Shahneen Sandhu,Célèste Lebbe,Paolo A. Ascierto,Georgina V. Long,Corey Ritchings,Ayman H. Nassar,Margarita Askelson,Melanie Pe Benito,Wenjia Wang,F. Stephen Hodi,James Larkin
摘要
Previous results from this trial showed longer overall survival after treatment with nivolumab plus ipilimumab or with nivolumab monotherapy than with ipilimumab monotherapy in patients with advanced melanoma. Given that patients with advanced melanoma are living longer than 7.5 years, longer-term data were needed to address new clinically relevant questions.
穆紫
凤凰
美好乐松
账户已注销
科目三
eternity136
陈军
一一
畅快的毛衣
JY
斯文败类
只谈风月
毛豆爸爸
Singularity
小蘑菇
华仔
CodeCraft
丘比特
逻辑猫
夏来
皖公网安备34019202002308
